Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an ex...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Yang, Shuqun, Luo, Chonglin, Gu, Qingyang, Xu, Qiang, Wang, Guan, Sun, Hongye, Qian, Ziliang, Tan, Yexiong, Qin, Yuxin, Shen, Yuhong, Xu, Xiaowei, Chen, Shu-Hui, Chan, Chi-Chung, Wang, Hongyang, Mao, Mao, Fang, Douglas D.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868698/
https://ncbi.nlm.nih.gov/pubmed/26701727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6684
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items